Evidence map›Paper›PMID 33660658›Full record

ArticleTransplantation2021

Impact of Advanced Renal Dysfunction on Posttransplant Outcomes After Living Donor Liver Transplantation in the United States.

Therese Bittermann, Peter L Abt, Kim M Olthoff, Navpreet Kaur, Julie K Heimbach, Juliet Emamaullee

Open access · greenAbstract read
In one paragraph

Article in Transplantation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Therese BittermannDivision of Gastroenterology and Hepatology, University of Pennsylvania, Philadelphia, PA.
Peter L AbtDivision of Transplant Surgery, University of Pennsylvania, Philadelphia, PA.
Kim M OlthoffDivision of Transplant Surgery, University of Pennsylvania, Philadelphia, PA.
Navpreet KaurDepartment of Surgery, University of Southern California, Los Angeles, CA.
Julie K HeimbachDepartment of Surgery, Mayo Clinic College of Medicine, Rochester, MN.
Juliet EmamaulleeDepartment of Surgery, University of Southern California, Los Angeles, CA.
University of Pennsylvania · USUniversity of Southern California · USMayo Clinic · US

Funding

Immunologic Biomarkers of Rejection in Clinical Liver TransplantationK08CA245220 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI EMAMAULLEE, JULIET · 2020 to 2024
$1.3M
Impact of immunosuppression variability on outcomes after liver transplantationK08DK117013 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI BITTERMANN, THERESE · 2018 to 2022
$932k
NCI NIH HHS K08 CA245220NIDDK NIH HHS K08 DK117013
6 · The paper itself

Abstract

backgroundSurvival after living donor liver transplantation (LDLT) in the United States is excellent. However, the significance of pretransplant kidney disease on outcomes in this population is poorly understood.

methodsThis was a retrospective cohort study of 2806 LDLT recipients nationally between January 2010 and June 2020. Recipients with estimated glomerular filtration rate <40 mL/min/1.73 m2 (eGFR-low) or requiring dialysis were compared. Multivariable survival analyses evaluated (1) eGFR-low as a predictor of post-LDLT survival and (2) the survival of LDLT versus deceased donor liver transplant (DDLT) alone with eGFR-low.

resultsFrom 2010 to 2020, 140 (5.0%) patients had eGFR-low and 18 (0.6%) required dialysis pre-LDLT. The number of LDLTs requiring dialysis between 2017 and 2020 outnumbered the prior 7 y. Overall LDLT experience was greater at centers performing LDLT in recipients with renal dysfunction (P < 0.001). LDLT recipients with eGFR-low had longstanding renal dysfunction: mean eGFR 3-6 mo before LDLT 42.7 (±15.1) mL/min/1.73 m2. Nearly half (5/12) of eGFR-low recipients with active kidney transplant (KT) listing at LDLT experienced renal recovery. Five patients underwent early KT after LDLT via the new "safety net" policy. Unadjusted survival after LDLT was worse with eGFR-low (hazard ratio 2.12 versus eGFR ≥40 mL/min/1.73 m2; 95% confidence interval, 1.47-3.05; P < 0.001), but no longer so when accounting for mean eGFR 3-6 mo pre-LDLT (hazard ratio, 1.27; 95% confidence interval, 0.82-1.95; P = 0.3). The adjusted survival of patients with eGFR-low receiving LDLT versus deceased donor liver transplant alone was not different (P = 0.08).

conclusionsOverall, outcomes after LDLT with advanced renal dysfunction are acceptable. These findings are relevant given the recent "safety net" KT policy.

Indexed as

Liver TransplantationGraft SurvivalHumansLiving DonorsProportional Hazards ModelsRetrospective StudiesTreatment OutcomeUnited States

Identifiers

PMID33660658
PMCPMC8410875
OpenAlexW3135892042

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.